Plasma phospholipid fatty acids in X-linked adrenoleukodystrophy

Clinical Chemistry

Volumn 42, Issue 3, 1996, Pages 454-461

  Aveldaño, Marta I ^a,c   Donnari, Domingo ^b  

^a UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

^b Hospital Interzonal Dr Jose Penna   (Argentina)

^c Instituto de Investigaciones Bioquimicas Bahia Blanca   (Argentina)

Author keywords

gene defect; genetic disorders; peroxisomal disease; sphingomyelin

Indexed keywords

FATTY ACID; GLYCEROPHOSPHOLIPID; LIGNOCERIC ACID; LINOLEIC ACID; OLEIC ACID; POLYUNSATURATED FATTY ACID; SPHINGOMYELIN;

ADRENOLEUKODYSTROPHY; ARTICLE; BLOOD CELL; CASE REPORT; CHILD; FATTY ACID BLOOD LEVEL; FATTY ACID DESATURATION; FATTY ACID METABOLISM; HUMAN; MALE;

EID: 0029925103     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.3.454     Document Type: Article

References (28)

1. Moser HW, Moser AB. Adrenoleukodystrophy (X-linked). In: Scriver AR, Beaudet AL, Sly WS, Valle D, eds. The metabolic basis of inherited disease, 6th ed., Vol. 2. New York: McGraw-Hill, 1989: 1511-32.
2. Singh I, Moser AB, Goldfischer S, Moser HW. Lignoceric acid is oxidized in the peroxisome: implications for the cerebro-hepatorenal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A 1984;81:4203-7.
3. Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A 1988;88:7647-51.
4. Wanders RJA, van Roermund CWT, van Wijland MJA, Schutgens RBH, van den Bosch H, Schram AW, Tager JM. Direct demonstration that the deficient oxidation of very long chain fatty acids in X-linked leukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem Biophys Res Commun 1988;153:618-24.
5. Wanders RJA, van Roermund CWT, van Wijland MJA, Nijenhuis AA, Tromp A, Schutgens RBH, et al. X-linked adrenoleukodystrophy: defective peroxisomal oxidation of very long chain fatty acids but not of very long chain fatty acyl-CoA esters. Clin Chim Acta 1987;165:321-9.
6. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993;361:726-30.
7. Moser HW, Moser AB, Frayer KK, Chen W, Schulman JD, O'Neill BP, Kishimoto I. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981;31: 1241-9.
8. Tsuji S, Suzuki M, Ariga T, Sekina M, Kuriyama M, Miyatake T. Abnormality of long chain fatty acids in erythrocyte membrane sphingomyelin from patients with adrenoleukodystrophy. J Neurochem 1981;36:1046-9.
9. Moser HW, Moser AB, Singh I, O'Neill BP. Adrenoleukodystrophy: survey of 303 cases: biochemistry, diagnosis, and therapy. Ann Neurol 1984;16:628-41.
10. Moser HW, Naidu S, Kumar AJ, Rosenbaum AE. Adrenoleukodystrophy: toward a biochemical definition of a disease with various presentations. CRC Crit Rev Neurobiol 1987;31:29-38.
11. Moser AB, Borel J, Odone A, Naidu S, Ciornblath D, Sanders DB, Moser HW. A new dietary therapy for adrenoleukodystrophy. Biochemical and preliminary clinical results in 36 patients. Ann Neurol 1987;21:240-9.
12. Rizzo WB, Leshner RT, Odone A, Damman AL, Craft DA, Jensen ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989;39:1415-22.
13. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
14. Rouser G, Fleischer S, Yamamoto A. Two dimensional thin layer chromatographic separation and analysis of phospholipids by phosphorus analysis of spots. Lipids 1970;5:494-6.
15. Morrison WR, Smith LM. Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. J Lipid Res 1964;5:600-8.
16. Igarashi M, Schamburg HH, Powers J, Kishimoto I, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976;26:851-60.
17. Miyatake T, Ariga T, Atsumi T, Koyima Y. Biochemical study on myelin in adrenoleukodystrophy. Adv Exp Med Biol 1978;100: 585-99.
18. Theda C, Moser AB, Powers JM, Moser HW. Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. J Neurol Sci 1992;110: 195-204.
19. Kawamura N, Moser AB, Moser HW, Ogino T, Suzuki K, Schamburg H, et al. High concentration of hexacosanoate in cultured skin fibroblast lipids from adrenoleukodystrophy patients. Biochem Biophys Res Commun 1978;82:114-20.
20. Sargent JR, Coupland K, Wilson R. Nervonic acid and demyelinating disease. Med Hypotheses 1994;42:237-42.
21. Poulos A, Gibson R, Sharp P, Beckman K, Grattansmith P. Very long chain fatty acids in X-ALD brain after treatment with Lorenzo's oil. Ann Neurol 1994;36:741-6.
22. Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:274-9.
23. Martínez M, Mougan I, Roig M, Ballabriga A. Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study. Lipids 1994;29:273-80.
24. Martínez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992;583:171-82.
25. Martínez M. Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids 1989;24:261-5.
26. Martínez M. Developmental profiles of polyunsaturated fatty acids in the brain of normal infants and patients with peroxisomal diseases: severe deficiency of docosahexaenoic acid in Zellweger's and pseudo-Zellweger's syndromes. World Rev Nutr Diet 1991;66:87-102.
27. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J Biol Chem 1991;266:19995-20000.
28. 32. J Biol Chem 1993;268:11663-9.